GO:0004821 histidine-tRNA ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004821 histidine-tRNA ligase activity catalyzes the ATP-dependent attachment of L-histidine to tRNA(His), producing L-histidyl-tRNA(His), AMP, and diphosphate.
• The enzyme, histidyl-tRNA synthetase (HisRS, gene HARS1 in humans), is a class II aminoacyl-tRNA synthetase that ensures translational fidelity.
• HisRS is not only a housekeeping enzyme; it has extracellular cytokine-like functions and is a target of autoantibodies in myositis and anti-synthetase syndrome.
• A splice variant of human HisRS (HARS1) can act therapeutically to resolve lung inflammation and fibrosis by targeting NRP2.
• In yeast and mammals, the related protein Gcn2 mimics HisRS structurally and repurposes it for the integrated stress response.
• Thg1, a tRNAHis guanylyltransferase, adds a critical G-1 to tRNA(His) and displays tRNA-inducible GTPase activity, highlighting the importance of tRNA(His) maturation.
Description
Histidine-tRNA ligase activity (GO:0004821) is a fundamental molecular function that ensures the correct incorporation of histidine into proteins during translation. This activity is catalyzed by histidyl-tRNA synthetase (HisRS), an enzyme that charges tRNA(His) with L-histidine in an ATP-dependent two-step reaction. The reaction proceeds via an aminoacyl-adenylate intermediate and results in the formation of L-histidyl-tRNA(His), which delivers histidine to the ribosome for protein synthesis. Beyond its canonical role in translation, HisRS has emerged as a multifunctional protein involved in cytokine signaling, immune responses, and disease pathogenesis. Understanding GO:0004821 is therefore critical for researchers studying translation, autoimmunity, and therapeutic interventions.
histidine-tRNA ligase activity At A Glance
| GO ID | GO:0004821 |
|---|---|
| GO term | histidine-tRNA ligase activity |
| Ontology | molecular_function |
| Synonym | histidyl-tRNA synthetase activity |
| Major function | Catalyzes the attachment of L-histidine to tRNA(His) for protein synthesis |
| Reaction | ATP + L-histidine + tRNA(His) = AMP + diphosphate + L-histidyl-tRNA(His) |
| Enzyme class | Class II aminoacyl-tRNA synthetase |
| Human gene | HARS1 |
What Is GO:0004821?
GO:0004821 histidine-tRNA ligase activity is defined as the catalysis of the reaction: ATP + L-histidine + tRNA(His) = AMP + diphosphate + L-histidyl-tRNA(His). This activity belongs to the class II aminoacyl-tRNA synthetases and is essential for protein biosynthesis.
Why Is histidine-tRNA ligase activity Important in Cell Biology?
Histidine-tRNA ligase activity is indispensable for accurate translation of the genetic code, as it ensures that histidine is correctly paired with its cognate tRNA. Errors in this process can lead to mistranslation and protein misfolding, which are associated with various diseases. Moreover, HisRS is a target of autoantibodies in idiopathic inflammatory myopathies and anti-synthetase syndrome, making it a key biomarker and potential therapeutic target. Recent studies have also revealed non-canonical functions of HisRS in immune modulation and fibrosis resolution, underscoring its broader biological significance.
• Essential for protein synthesis and translational fidelity.
• Autoantigen in myositis and anti-synthetase syndrome.
• Splice variant of HARS1 has therapeutic potential in lung inflammation and fibrosis.
• Structurally mimicked by Gcn2 for integrated stress response.
• tRNA(His) maturation requires Thg1-mediated guanylylation.
• Target for aptamer-tagged tRNA studies.
• Molecular recognition of tRNA(His) by HisRS is well-characterized in archaea.
• Involved in cytokine-like signaling and immune regulation.
• Potential role in cancer and neurodegenerative diseases through translational control.
• Enables research on aminoacyl-tRNA synthetase inhibitors as antimicrobials.
What Happens During histidine-tRNA ligase activity?
Substrate Binding and Aminoacyl-Adenylate Formation
In simple terms: The enzyme first grabs histidine and ATP to make an activated intermediate.
HisRS binds L-histidine and ATP in its catalytic site, facilitating the formation of histidyl-adenylate (His-AMP) with the release of pyrophosphate. This step is highly specific and requires a conserved class II synthetase motif.
tRNA(His) Recognition and Aminoacylation
In simple terms: The activated histidine is then transferred onto the tRNA molecule.
The enzyme recognizes the unique structural features of tRNA(His), including the acceptor stem and the G-1 nucleotide, and transfers the histidyl moiety to the 3'-OH of the tRNA's terminal adenosine, forming L-histidyl-tRNA(His) and releasing AMP.
Proofreading and Editing
In simple terms: The enzyme double-checks to avoid attaching the wrong amino acid.
Although HisRS is generally accurate, it possesses editing activity to hydrolyze misactivated amino acids, ensuring translational fidelity. This proofreading is crucial for preventing mistranslation.
Non-canonical Functions and Secretion
In simple terms: Some of this enzyme can leave the cell and act like a signal molecule.
Beyond translation, HisRS can be secreted or spliced into variants that act as cytokines, modulating immune responses and angiogenesis. For example, a human HisRS splice variant targets NRP2 to resolve lung inflammation.
Key Genes Involved in GO:0004821 histidine-tRNA ligase activity
The following genes and proteins are directly or functionally associated with histidine-tRNA ligase activity (GO:0004821).
| Gene | Major Role | Research Relevance |
|---|---|---|
| HARS1 | Human histidyl-tRNA synthetase; catalyzes histidine-tRNA charging | Autoantigen in myositis; therapeutic splice variant |
| HARS2 | Mitochondrial histidyl-tRNA synthetase | Mitochondrial translation; mutations linked to Perrault syndrome |
| GCN2 | EIF2AK4; kinase that mimics HisRS for integrated stress response | Structural mimicry of HisRS; stress response |
| THG1L | tRNA(His) guanylyltransferase; adds G-1 to tRNA(His) | tRNA maturation; GTPase activity |
| NARS1 | Asparaginyl-tRNA synthetase | Comparative synthetase studies |
| DARS1 | Aspartyl-tRNA synthetase | Comparative synthetase studies |
| YARS1 | Tyrosyl-tRNA synthetase | Cytokine-like functions |
| AARS1 | Alanyl-tRNA synthetase | Editing and disease |
| MARS1 | Methionyl-tRNA synthetase | Autoantigen in myositis |
| KARS1 | Lysyl-tRNA synthetase | Autoantigen in myositis |
| IARS1 | Isoleucyl-tRNA synthetase | Autoantigen in myositis |
| LARS1 | Leucyl-tRNA synthetase | Autoantigen in myositis |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase | Autoantigen in myositis |
| QARS1 | Glutaminyl-tRNA synthetase | Autoantigen in myositis |
| RARS1 | Arginyl-tRNA synthetase | Autoantigen in myositis |
| SARS1 | Seryl-tRNA synthetase | Autoantigen in myositis |
| VARS1 | Valyl-tRNA synthetase | Autoantigen in myositis |
| WARS1 | Tryptophanyl-tRNA synthetase | Autoantigen in myositis |
How Is histidine-tRNA ligase activity Regulated?
Histidine-tRNA ligase activity is regulated at multiple levels. In the integrated stress response, the kinase Gcn2 (EIF2AK4) structurally mimics HisRS and is activated by uncharged tRNA, leading to phosphorylation of eIF2α and translational reprogramming. Additionally, HisRS expression can be induced by immune stimuli, and its secretion is regulated by alternative splicing. The activity of Thg1, which modifies tRNA(His), is regulated by tRNA availability and GTP levels.
histidine-tRNA ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HARS1 | Anti-synthetase syndrome, myositis | Knockout mice, autoantibody transfer models |
| HARS1 | Lung inflammation and fibrosis | Splice variant overexpression in mouse lung injury models |
| HARS2 | Perrault syndrome | Patient-derived fibroblasts, mitochondrial translation assays |
| GCN2 | Integrated stress response in cancer and neurodegeneration | Gcn2 knockout mice, stress induction models |
| THG1L | tRNA(His) maturation defects | Yeast and human cell lines with THG1L mutations |
Autoimmune Myositis and Anti-Synthetase Syndrome
Histidyl-tRNA synthetase is a major autoantigen in idiopathic inflammatory myopathies, particularly anti-synthetase syndrome. Autoantibodies against HisRS (anti-Jo-1) are found in a subset of patients and correlate with interstitial lung disease and arthritis. Epitope studies indicate that HisRS is a stimulating antigen in idiopathic myositis, driving T-cell and B-cell responses.
Lung Inflammation and Fibrosis
A naturally occurring splice variant of human HisRS has been shown to target neuropilin-2 (NRP2) and resolve lung inflammation and fibrosis in preclinical models. This variant acts as a therapeutic agent by modulating immune cell recruitment and cytokine production.
Mitochondrial Diseases and Perrault Syndrome
Mutations in HARS2, the mitochondrial histidyl-tRNA synthetase, are associated with Perrault syndrome, characterized by sensorineural hearing loss and ovarian dysgenesis. These mutations impair mitochondrial translation and energy metabolism.
Cancer and Translational Control
Dysregulation of aminoacyl-tRNA synthetases, including HisRS, has been implicated in cancer progression through effects on translation and angiogenesis. HisRS can promote cell migration and invasion via its cytokine-like functions, making it a potential target for anticancer therapy.
From histidine-tRNA ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does HARS1 loss impair translation? | HARS1 knockout cell lines (e.g., HEK293T) with polysome profiling |
| What is the role of HisRS in autoimmunity? | HARS1 knock-in mice expressing human autoantigenic epitopes |
| Can HisRS splice variant resolve fibrosis? | Overexpression of splice variant in bleomycin-induced lung fibrosis mouse model |
| How does Gcn2 mimic HisRS? | Point mutations in GCN2 to disrupt HisRS-like domain, followed by stress assays |
| What is the impact of HARS2 mutations on mitochondria? | Knock-in of patient mutations in HARS2 in human cells, respirometry |
| Does Thg1 GTPase activity affect tRNA charging? | THG1L knockout yeast, tRNA sequencing and GTPase assays |
How to Study the histidine-tRNA ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aminoacylation assay | His-tRNA(His) formation | Enzyme kinetics, inhibitor screening |
| Ribo-seq | Global translation and ribosome occupancy | Effect of HisRS depletion on translation |
| Polysome profiling | Distribution of mRNAs on polysomes | Translational control studies |
| ELISA | Anti-HisRS autoantibodies | Diagnosis of myositis |
| Crystallography | 3D structure of HisRS-tRNA complex | Mechanistic studies |
| GTPase assay | GTP hydrolysis by Thg1 | tRNA maturation studies |
| Aptamer-tagged tRNA | tRNA labeling and tracking | tRNA delivery and imaging |
Aminoacylation Assays
In vitro aminoacylation assays using purified HisRS and tRNA(His) measure the formation of L-histidyl-tRNA(His) by acid-urea gel electrophoresis or scintillation counting. These assays are used to determine kinetic parameters and inhibitor efficacy.
Ribo-seq and Polysome Profiling
Ribosome profiling (Ribo-seq) and polysome profiling assess global translation and codon-specific effects upon HisRS depletion or inhibition. These methods reveal changes in translation efficiency and ribosome pausing at histidine codons.
Autoantibody Detection
ELISA and immunoprecipitation are used to detect anti-HisRS autoantibodies in patient sera, aiding diagnosis of anti-synthetase syndrome. Epitope mapping can identify immunodominant regions.
Structural Biology
X-ray crystallography and cryo-EM provide high-resolution structures of HisRS in complex with tRNA(His) and ATP analogs, revealing molecular recognition mechanisms and conformational changes during catalysis.
How CRISPR Can Be Used to Study GO:0004821 histidine-tRNA ligase activity
Knockout
CRISPR-Cas9 knockout of HARS1 in human cell lines abolishes histidine-tRNA ligase activity, leading to histidine auxotrophy and impaired translation. These models are used to study the essentiality of HisRS and to identify compensatory pathways.
Point Mutation
Point mutations in the catalytic domain of HARS1 (e.g., in the class II motif) can be introduced to dissect the aminoacylation mechanism and to model patient-derived mutations. Such models help distinguish between canonical and non-canonical functions.
Knock-in
Knock-in of disease-associated HARS2 mutations or of tagged HARS1 alleles allows tracking of HisRS localization and function in vivo. These models are valuable for studying mitochondrial translation and Perrault syndrome.
Overexpression
Overexpression of wild-type or splice variant HARS1 in cell lines or mouse models is used to investigate its cytokine-like functions and therapeutic potential in inflammation and fibrosis.
How EDITGENE Supports histidine-tRNA ligase activity Research
Researchers studying histidine-tRNA ligase activity-related genes often need to determine whether a candidate gene is causally involved in translation, autoimmunity, or fibrosis. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for histidine-tRNA ligase activity research.
Frequently Asked Questions About histidine-tRNA ligase activity
What is histidine-tRNA ligase activity?
Histidine-tRNA ligase activity (GO:0004821) is the enzymatic function that attaches L-histidine to tRNA(His) using ATP, forming L-histidyl-tRNA(His) for protein synthesis.
What genes are involved in histidine-tRNA ligase activity?
The primary human gene is HARS1, encoding histidyl-tRNA synthetase. HARS2 encodes the mitochondrial isoform, and GCN2 (EIF2AK4) mimics HisRS structurally.
What diseases are associated with histidine-tRNA ligase activity?
Dysfunction or autoimmunity against HisRS is linked to myositis, anti-synthetase syndrome, lung fibrosis, and Perrault syndrome.
How is histidine-tRNA ligase activity regulated?
It is regulated by substrate availability, the integrated stress response via Gcn2, and alternative splicing that produces cytokine-like variants.
What is the role of HARS1 in autoimmunity?
HARS1 is a major autoantigen in idiopathic inflammatory myopathies; anti-Jo-1 antibodies target HisRS and correlate with interstitial lung disease.
Can histidine-tRNA ligase be targeted therapeutically?
Yes, a splice variant of human HisRS has shown therapeutic efficacy in resolving lung inflammation and fibrosis by targeting NRP2.
What methods are used to study histidine-tRNA ligase activity?
Common methods include aminoacylation assays, Ribo-seq, polysome profiling, ELISA for autoantibodies, and structural biology.
What is the difference between HARS1 and HARS2?
HARS1 encodes the cytoplasmic histidyl-tRNA synthetase, while HARS2 encodes the mitochondrial isoform; mutations in HARS2 cause Perrault syndrome.
How does Gcn2 relate to histidine-tRNA ligase?
Gcn2 structurally mimics HisRS and is activated by uncharged tRNA to trigger the integrated stress response.
What is the role of Thg1 in histidine-tRNA biology?
Thg1 adds a guanine nucleotide (G-1) to tRNA(His), which is essential for its maturation and recognition by HisRS; it also exhibits GTPase activity.
Conclusion
Histidine-tRNA ligase activity (GO:0004821) is a cornerstone of protein synthesis, catalyzed by the multifunctional enzyme HisRS. Its roles extend beyond translation to immune modulation, autoimmunity, and fibrosis, making it a compelling target for basic and clinical research. Advanced CRISPR models and multi-omics approaches will continue to unravel its complex biology and therapeutic potential.
References
- 1. Freist W et al.. 1999. Histidyl-tRNA synthetase.. Biol Chem 380(6):623-46 PMID: 10430027
- 2. Bou-Nader C et al.. 2024. Gcn2 structurally mimics and functionally repurposes the HisRS enzyme for the integrated stress response.. Proc Natl Acad Sci U S A 121(35):e2409628121 PMID: 39163341
- 3. Antika TR et al.. 2022. Human Thg1 displays tRNA-inducible GTPase activity.. Nucleic Acids Res 50(17):10015-10025 PMID: 36107775
- 4. Gayed C et al.. 2018. Immunopathogenesis of the Anti-Synthetase Syndrome.. Crit Rev Immunol 38(4):263-278 PMID: 30806243
- 5. Nangle LA et al.. 2025. A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis.. Sci Transl Med 17(789):eadp4754 PMID: 40073151
- 6. Mukai T. 2020. Rational Design of Aptamer-Tagged tRNAs.. Int J Mol Sci 21(20) PMID: 33096801
- 7. Nagatoyo Y et al.. 2005. Molecular recognition of histidine tRNA by histidyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1.. Nucleic Acids Symp Ser (Oxf) PMID: 17150756
- 8. Martin A et al.. 1995. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis.. FASEB J 9(12):1226-33 PMID: 7672516
